{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T02:22:45Z","timestamp":1786760565581,"version":"build-2736575974"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T00:00:00Z","timestamp":1721606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Gilead Sciences, K.K."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-67837-6","type":"journal-article","created":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T14:02:41Z","timestamp":1721656961000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Relationship between adherence to bictegravir\/emtricitabine\/tenofovir alafenamide fumarate and clinical outcomes in people with HIV in Japan: a claims database analysis"],"prefix":"10.1038","volume":"14","author":[{"given":"Nao","family":"Taguchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Rubino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"KuanYeh","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetsuya","family":"Tanikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,22]]},"reference":[{"key":"67837_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/21556660.2022.2149963","volume":"12","author":"BO Taiwo","year":"2023","unstructured":"Taiwo, B. O. et al. Treatment and comorbidity burden among people living with HIV: A review of systematic literature reviews. J. Drug Assess. 12, 1\u201311 (2023).","journal-title":"J. Drug Assess."},{"key":"67837_CR2","doi-asserted-by":"publisher","first-page":"21","DOI":"10.7326\/0003-4819-133-1-200007040-00004","volume":"133","author":"DL Paterson","year":"2000","unstructured":"Paterson, D. L. et al. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection. Ann. Intern. Med. 133, 21\u201330 (2000).","journal-title":"Ann. Intern. Med."},{"key":"67837_CR3","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1089\/apc.2014.0165","volume":"29","author":"LL Gordon","year":"2015","unstructured":"Gordon, L. L., Gharibian, D., Chong, K. & Chun, H. Comparison of HIV virologic failure rates between patients with variable adherence to three antiretroviral regimen types. AIDS Patient Care STDs 29, 384\u2013388 (2015).","journal-title":"AIDS Patient Care STDs"},{"key":"67837_CR4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1097\/QAI.0000000000002142","volume":"82","author":"KK Byrd","year":"2019","unstructured":"Byrd, K. K. et al. Antiretroviral adherence level necessary for HIV viral suppression using real-world data. JAIDS J. Acquir. Immune Defic. Syndr. 82, 245\u2013251 (2019).","journal-title":"JAIDS J. Acquir. Immune Defic. Syndr."},{"key":"67837_CR5","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1080\/13696998.2021.1995868","volume":"24","author":"J Priest","year":"2021","unstructured":"Priest, J. et al. Retrospective analysis of adherence to HIV treatment and healthcare utilization in a commercially insured population. J. Med. Econ. 24, 1204\u20131211 (2021).","journal-title":"J. Med. Econ."},{"key":"67837_CR6","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.jiac.2022.07.005","volume":"28","author":"X Wang","year":"2022","unstructured":"Wang, X., Schmerold, L. & Naito, T. Real-world medication persistence among HIV-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan. J. Infect. Chemother. 28, 1464\u20131470 (2022).","journal-title":"J. Infect. Chemother."},{"key":"67837_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s12981-020-00268-1","volume":"17","author":"J Cohen","year":"2020","unstructured":"Cohen, J. et al. Real-world adherence and persistence for newly-prescribed HIV treatment: Single versus multiple tablet regimen comparison among US medicaid beneficiaries. AIDS Res. Ther. 17, 12 (2020).","journal-title":"AIDS Res. Ther."},{"key":"67837_CR8","unstructured":"Research Group for Establishment of Team Medical Care and Improvement of Medical Standard in HIV Infection and Hemophilia. Guidelines for Anti-HIV Treatment., https:\/\/hiv-guidelines.jp\/index.htm (2023)."},{"key":"67837_CR9","doi-asserted-by":"publisher","first-page":"232595822211402","DOI":"10.1177\/23259582221140208","volume":"21","author":"FMD Maggiolo","year":"2022","unstructured":"Maggiolo, F. M. D. et al. Real world data on forgiveness to uncomplete adherence to bictegravir\/ emtricitabine\/tenofovir alafenamide. J. Int. Assoc. Provid. AIDS Care 21, 23259582221140210 (2022).","journal-title":"J. Int. Assoc. Provid. AIDS Care"},{"key":"67837_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad500.1396","author":"K Andreatta","year":"2023","unstructured":"Andreatta, K. et al. Efficacy of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) versus dolutegravir (DTG)-based 3-drug regimens in adults with HIV who have suboptimal antiretroviral adherence. Open Forum Infect. Dis. https:\/\/doi.org\/10.1093\/ofid\/ofad500.1396 (2023).","journal-title":"Open Forum Infect. Dis."},{"key":"67837_CR11","doi-asserted-by":"publisher","first-page":"583","DOI":"10.3390\/jpm13040583","volume":"13","author":"B Sellem","year":"2023","unstructured":"Sellem, B. et al. Intermittent bictegravir\/emtricitabine\/tenofovir alafenamide treatment maintains high level of viral suppression in virally suppressed people living with HIV. J. Pers. Med. 13, 583 (2023).","journal-title":"J. Pers. Med."},{"key":"67837_CR12","doi-asserted-by":"publisher","first-page":"101991","DOI":"10.1016\/j.eclinm.2023.101991","volume":"59","author":"PE Sax","year":"2023","unstructured":"Sax, P. E. et al. Bictegravir\/emtricitabine\/tenofovir alafenamide as initial treatment for HIV-1: Five-year follow-up from two randomized trials. EClinicalMedicine 59, 101991 (2023).","journal-title":"EClinicalMedicine"},{"key":"67837_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/hiv.13319","volume":"24","author":"F Maggiolo","year":"2023","unstructured":"Maggiolo, F. et al. Bictegravir\/emtricitabine\/tenofovir alafenamide in older individuals with HIV: Results of a 96-week, phase 3b, open-label, switch trial in virologically suppressed people >\/=65 years of age. HIV Med. 24, 27\u201336 (2023).","journal-title":"HIV Med."},{"key":"67837_CR14","doi-asserted-by":"publisher","first-page":"e485","DOI":"10.1093\/cid\/ciaa988","volume":"73","author":"PE Sax","year":"2021","unstructured":"Sax, P. E. et al. Switching to bictegravir, emtricitabine, and tenofovir alafenamide in virologically suppressed adults with human immunodeficiency virus. Clin. Infect. Dis. 73, e485\u2013e493 (2021).","journal-title":"Clin. Infect. Dis."},{"key":"67837_CR15","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1016\/S2352-4642(21)00165-6","volume":"5","author":"AH Gaur","year":"2021","unstructured":"Gaur, A. H. et al. Fixed-dose combination bictegravir, emtricitabine, and tenofovir alafenamide in adolescents and children with HIV: Week 48 results of a single-arm, open-label, multicentre, phase 2\/3 trial. Lancet Child Adolesc. Health 5, 642\u2013651 (2021).","journal-title":"Lancet Child Adolesc. Health"},{"key":"67837_CR16","unstructured":"Medical Data Vision Co., L. MDV EBM insight, https:\/\/www.mdv.co.jp\/ebm\/ (2023)."},{"key":"67837_CR17","unstructured":"JMDC Inc. JMDC Claims Database, https:\/\/www.jmdc.co.jp\/jmdc-claims-database\/ (2023)."},{"key":"67837_CR18","first-page":"163","volume":"44","author":"Y Yokomaku","year":"2023","unstructured":"Yokomaku, Y. Toward the establishment of a sustainable system for collecting and analysing information of HIV\/AIDS treatment in Japan. Infect. Agents Surveill. Rep. 44, 163\u2013164 (2023).","journal-title":"Infect. Agents Surveill. Rep."},{"key":"67837_CR19","unstructured":"Nau D. Proportion of Days Covered (PDC) as a Preferred Method of Measuring Medication Adherence, http:\/\/ep.yimg.com\/ty\/cdn\/epill\/pdcmpr.pdf (2011)."},{"key":"67837_CR20","unstructured":"Japan Agency for Medical Research and Development, Research Project for Practical AIDS Control. Guideline for HIV Drug Resistance Test. version 10, https:\/\/www.hiv-resistance.jp\/pdf\/hiv_resistance_guideline_v10.pdf (2017)."},{"key":"67837_CR21","unstructured":"Pharmacy Quality Alliance. Adherence Measures., https:\/\/www.pqaalliance.org\/index.php?option=com_content&view=article&id=610:adherence-measures&catid=32:measures (2022)."},{"key":"67837_CR22","doi-asserted-by":"publisher","first-page":"4961","DOI":"10.1007\/s12325-021-01883-8","volume":"38","author":"GA McComsey","year":"2021","unstructured":"McComsey, G. A., Lingohr-Smith, M., Rogers, R., Lin, J. & Donga, P. Real-world adherence to antiretroviral therapy among HIV-1 patients across the United States. Adv. Ther. 38, 4961\u20134974 (2021).","journal-title":"Adv. Ther."},{"key":"67837_CR23","first-page":"294","volume":"24","author":"D Watanabe","year":"2022","unstructured":"Watanabe, D. et al. Efficacy, safety and tolerability of bictegravir\/emtricitabine\/tenofovir alafenamide (B\/F\/TAF) in clinical practice: Results of a 12-month analysis of BICSTaR Japan (2nd). J. AIDS Res. 24, 294 (2022).","journal-title":"J. AIDS Res."},{"key":"67837_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1128\/AAC.02533-18","volume":"63","author":"RK Acosta","year":"2019","unstructured":"Acosta, R. K. et al. Resistance analysis of bictegravir-emtricitabine-tenofovir alafenamide in HIV-1 treatment-naive patients through 48 weeks. Antimicrob. Agents Chemother. 63, 10\u20131128 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"67837_CR25","doi-asserted-by":"publisher","first-page":"e347","DOI":"10.1016\/S2352-3018(18)30091-2","volume":"5","author":"ES Daar","year":"2018","unstructured":"Daar, E. S. et al. Efficacy and safety of switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from boosted protease inhibitor-based regimens in virologically suppressed adults with HIV-1: 48 week results of a randomised, open-label, multicentre, phase 3, non-inferiority trial. Lancet HIV 5, e347\u2013e356 (2018).","journal-title":"Lancet HIV"},{"key":"67837_CR26","doi-asserted-by":"publisher","first-page":"e357","DOI":"10.1016\/S2352-3018(18)30092-4","volume":"5","author":"JM Molina","year":"2018","unstructured":"Molina, J. M. et al. Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial. Lancet HIV 5, e357\u2013e365 (2018).","journal-title":"Lancet HIV"},{"key":"67837_CR27","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.jgar.2022.06.027","volume":"30","author":"D Armenia","year":"2022","unstructured":"Armenia, D. et al. Bictegravir\/emtricitabine\/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice. J. Glob. Antimicrob. Resist. 30, 326\u2013334 (2022).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"67837_CR28","doi-asserted-by":"publisher","first-page":"e019985","DOI":"10.1136\/bmjopen-2017-019985","volume":"8","author":"DJ Ruzicka","year":"2018","unstructured":"Ruzicka, D. J., Imai, K., Takahashi, K. & Naito, T. Comorbidities and the use of comedications in people living with HIV on antiretroviral therapy in Japan: A cross-sectional study using a hospital claims database. BMJ Open 8, e019985 (2018).","journal-title":"BMJ Open"},{"key":"67837_CR29","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1016\/j.jiac.2018.10.006","volume":"25","author":"DJ Ruzicka","year":"2019","unstructured":"Ruzicka, D. J., Imai, K., Takahashi, K. & Naito, T. Greater burden of chronic comorbidities and co-medications among people living with HIV versus people without HIV in Japan: A hospital claims database study. J. Infect. Chemother. 25, 89\u201395 (2019).","journal-title":"J. Infect. Chemother."},{"key":"67837_CR30","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1111\/hiv.13206","volume":"23","author":"T Naito","year":"2022","unstructured":"Naito, T. et al. Comorbidities and co-medications among 28 089 people living with HIV: A nationwide cohort study from 2009 to 2019 in Japan. HIV Med. 23, 485\u2013493 (2022).","journal-title":"HIV Med."},{"key":"67837_CR31","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1186\/s12879-019-4129-6","volume":"19","author":"DJ Ruzicka","year":"2019","unstructured":"Ruzicka, D. J., Kuroishi, N., Oshima, N., Sakuma, R. & Naito, T. Switch rates, time-to-switch, and switch patterns of antiretroviral therapy in people living with human immunodeficiency virus in Japan, in a hospital-claim database. BMC Infect. Dis. 19, 505 (2019).","journal-title":"BMC Infect. Dis."},{"key":"67837_CR32","doi-asserted-by":"publisher","first-page":"1732","DOI":"10.1038\/s41598-022-05816-5","volume":"12","author":"T Naito","year":"2022","unstructured":"Naito, T. et al. Analysis of antiretroviral therapy switch rate and switching pattern for people living with HIV from a national database in Japan. Sci. Rep. 12, 1732 (2022).","journal-title":"Sci. Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67837-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67837-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67837-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,22]],"date-time":"2024-07-22T14:06:03Z","timestamp":1721657163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-67837-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,22]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["67837"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-67837-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,22]]},"assertion":[{"value":"22 December 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 July 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NT, YP, AR, KL, MC, KH and TT are Gilead employees and stockholders. TN has received research grants from Gilead Sciences, consulting fees from Nobelpharma Co., Ltd., and TSUMURA & CO., and he has received lecture fees from MSD K.K., ViiV Healthcare and Gilead Sciences.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"16785"}}